Webinars

Taking a novel approach to drug development

Webinars

Explore Lantern Pharma’s Key Opinion Leader Webinar Series — where leaders in oncology, AI-driven drug discovery, and clinical research share insights shaping the future of precision cancer treatment. Watch past sessions featuring world-renowned experts and learn how Lantern’s RADR^® platform and innovative drug candidates are advancing cancer therapy development.

From Discovery to Clinical Trials to Patients: Key Decisions Shaping Novel CNS Oncology Medicines

From Discovery to Clinical Trials to Patients: Key Decisions Shaping Novel CNS Oncology Medicines

Lantern Pharma CEO and President Panna Sharma sits down with newly appointed Board Member Dr. Lee Schalop — co-founder of Oncoceutics and one of the leaders behind the development of ONC201 (Dordaviprone) — for a thoughtful discussion on the future of CNS oncology drug development.

September 29, 2025

Webinar Wednesday - Power of AI in Drug Development-Predicting Blood Brain Barrier Permeability with RADR

Webinar Wednesday - Power of AI in Drug Development-Predicting Blood Brain Barrier Permeability with RADR

Webinar focusing on the power of AI in drug development, highlighting how Lantern's proprietary RADR® platform is used to predict blood-brain barrier (BBB) permeability—a critical factor in developing effective treatments for brain cancers. The webinar featured Rick Fontenot, M.S., Data Scientist at Lantern Pharma, who discussed the role of AI, machine learning, and genomics in identifying drug candidates that can successfully cross the BBB, and shed light on how RADR® accelerates precision oncology drug development.

December 11, 2024

Webinar Wednesday - Actuate Therapeutics x Lantern Pharma AI Collaboration "The Elraglusib Story"

Webinar Wednesday - Actuate Therapeutics x Lantern Pharma AI Collaboration "The Elraglusib Story"

Showcasing how artificial intelligence in drug development is accelerating and enhancing the progress of the novel cancer therapy Elraglusib - in collaboration with Actuate Therapeutics. The webinar speakers included Andrew Mazar, Chief Operating Officer of Actuate Therapeutics, and Joseph McDermott, Computational Biologist at Lantern Pharma, who discussed how Lantern’s proprietary RADR® AI platform supports precision medicine, enables data-driven oncology research, improves patient selection, and streamlines clinical development.

October 30, 2024

Webinar Wednesday - Childhood Cancer Awareness Month - LP-184 with THREE additional RPDDs in rare children’s cancers

Webinar Wednesday - Childhood Cancer Awareness Month - LP-184 with THREE additional RPDDs in rare children’s cancers

Lantern Pharma leaders Panna Sharma, CEO & President, and Dr. Reggie Ewesuedo, VP of Clinical Development, announced a major advancement in pediatric oncology as we continue our mission to combat rare and difficult-to-treat cancers. In this webinar, Lantern shares that LP-184 has received three additional FDA Rare Pediatric Disease Designations, specifically targeting ultra-rare and hard-to-treat childhood cancers.

September 25, 2024

Webinar Wednesday - Harmonic Phase 2 Trial Preliminary Data Readout

Webinar Wednesday - Harmonic Phase 2 Trial Preliminary Data Readout

Explore the latest insights from Lantern Pharma’s Harmonic™ clinical trial, a groundbreaking study focused on never-smokers with non-small cell lung cancer (NSCLC). In this session, Dr. Reggie Ewesuedo, VP of Clinical Development at Lantern Pharma, discusses the trial design, early clinical findings, and how these results may shape the future of cancer treatment.

August 28, 2024

Webinar Wednesday - Starlight Therapeutics - Born from AI, Lighting the Way in CNS Cancer Treatment

Webinar Wednesday - Starlight Therapeutics - Born from AI, Lighting the Way in CNS Cancer Treatment

From concept to clinic, Starlight Therapeutics is harnessing the power of artificial intelligence to transform the treatment of central nervous system (CNS) cancers. In this webinar with Lantern Pharma CEO and President Panna Sharma, we take an in-depth look at the vision, innovations, and future roadmap driving this pioneering effort to bring new hope to patients with rare and hard-to-treat brain tumors.

July 31, 2024

Webinar Wednesday - STAR-001 in Multiple Brain and CNS Cancers

Webinar Wednesday - STAR-001 in Multiple Brain and CNS Cancers

This webinar features Dr. Marc Chamberlain, Chief Medical Officer at Lantern Pharma, as he discusses STAR-001 — an innovative targeted therapy in development for multiple brain and central nervous system (CNS) cancers. Developed by Starlight Therapeutics, a Lantern Pharma company, STAR-001 is being advanced with a focus on some of the most aggressive and underserved tumor types.

June 26, 2024

Bladder Cancer Awareness Month Webinar - Precision Medicine for Bladder Cancer: Now is the Time

Bladder Cancer Awareness Month Webinar - Precision Medicine for Bladder Cancer: Now is the Time

In this webinar, Dr. Helle Pappot from the University of Copenhagen (UCPH) discusses the urgent need for new treatment strategies in bladder cancer and the growing role of precision medicine in improving patient outcomes. Featuring insights from Lantern Pharma, the session highlights how advances in biomarkers and AI-driven research are helping develop more targeted and effective therapies.

May 31, 2024

Webinar Wednesday - LP-184 in Pancreatic Cancer and Other Solid Tumors

Webinar Wednesday - LP-184 in Pancreatic Cancer and Other Solid Tumors

In this webinar, Dr. Igor Astsaturov from Fox Chase Cancer Center (FCCC) discusses the urgent need for new treatment options in pancreatic cancer and other solid tumors, and how LP-184 is being developed to address these challenges through targeted, AI-enabled drug discovery.

May 29, 2024

Webinar Wednesday - LP-300 in never smokers with non-Small Cell Lung cancer

Webinar Wednesday - LP-300 in never smokers with non-Small Cell Lung cancer

This webinar features Dr. Joseph Treat from Fox Chase Cancer Center (FCCC), who discusses the unique clinical landscape of never-smokers with non-small cell lung cancer (NSCLC) and how LP-300 may offer a new precision-based therapeutic option.

April 24, 2024

Synthetic Lethality KOL Webinar

Synthetic Lethality KOL Webinar

This webinar features Dr. Zoltan Szallasi, an expert in synthetic lethality and DNA damage repair (DDR)-deficient tumors. Dr. Szallasi discusses how synthetic lethality is being applied in oncology and highlights the potential of LP-184—alone or in combination with FDA-approved agents—to enhance anti-tumor activity in DDR-deficient cancers.

March 21, 2023

Childhood Cancer Awareness Month KOL Webinar

Childhood Cancer Awareness Month KOL Webinar

Featuring Dr. Peter Houghton, Professor and Principal Investigator at the Greehey Children’s Cancer Research Institute (UT Health Science Center–San Antonio), this session examines key challenges in pediatric cancer research and highlights new preclinical data showing LP-284’s efficacy in several pediatric cancer models, including Ewing’s sarcoma, malignant rhabdoid tumors, and alveolar rhabdomyosarcoma.

September 22, 2022

Brain Tumor Awareness Month GBM KOL Webinar

Brain Tumor Awareness Month GBM KOL Webinar

Drs. John Laterra and Matthias Holdhoff of Johns Hopkins University, together with Dr. Kishor Bhatia, Chief Scientific Officer at Lantern Pharma, discuss the current landscape of glioblastoma (GBM) treatment, the challenges patients face, and how Lantern’s drug candidate LP-184 is being developed to address these needs across GBM and other brain cancers.

May 26, 2022

World Pancreatic Cancer Day KOL Webinar

World Pancreatic Cancer Day KOL Webinar

Dr. Igor Astsaturov of Fox Chase Cancer Center, Dr. Ira Sharp - pancreatic cancer survivor and patient advocate, and Kishor Bhatia, Chief Scientific Officer of Lantern Pharma discuss the latest advances of LP-184 - a PTGR1-activated small molecule designed to exploit DNA repair deficiencies and selectively target pancreatic cancers. The session also explores the potential clinical applications of LP-184 as it progresses toward a Phase 1 trial.

November 18, 2021